LIMN (Liminatus Pharma) Tariff Resilience Score: 8/10 (As of Jul. 04, 2026)


LIMN Liminatus Pharma Inc LIMN
13 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Liminatus Pharma Tariff Resilience Score?

Liminatus Pharma LIMN +22.63% 13 Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus rates LIMN with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,373 Biotechnology companies, Liminatus Pharma ranks better than 98.69% on this metric.

Liminatus Pharma has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Liminatus Pharma has Liminatus Pharma, a biotech firm, has minimal exposure to tariffs as its operations focus on R&D rather than manufacturing. The industry benefits from exemptions on medical and pharmaceutical products.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Liminatus Pharma might have Highly Resilient.

Liminatus Pharma  (NAS:LIMN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Liminatus Pharma Tariff Resilience Score Related Terms

LIMN vs GNPX, PCSA, ELAB: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Liminatus Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Liminatus Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liminatus Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Liminatus Pharma's Tariff Resilience Score falls into.


LIMN
13GF Score
Liminatus Pharma Inc LIMN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Liminatus Pharma (LIMN) has a Tariff Resilience Score of 8 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Liminatus Pharma ranks #18 out of 1373 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Liminatus Pharma's Tariff Resilience Score too high?
Liminatus Pharma's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Liminatus Pharma's value of 8 is 100% above this industry median. Based on the distribution chart, Liminatus Pharma ranks #18 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Liminatus Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Liminatus Pharma's Tariff Resilience Score compare to GNPX and PCSA?
According to the Biotechnology industry distribution chart, Liminatus Pharma ranks #18 out of 1373 companies for Tariff Resilience Score. This places Liminatus Pharma in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Liminatus Pharma's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liminatus Pharma's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liminatus Pharma's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liminatus Pharma stock overvalued right now?
Liminatus Pharma (LIMN) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Liminatus Pharma's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Liminatus Pharma (LIMN), the current Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Liminatus Pharma Business Description

Address 12611 Hiddencreek Way, Unit C, Cerritos, CA, USA, 90703
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
13GF Score

Get the complete analysis for LIMN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price